Loading clinical trials...

The Clinical Application Value of "Showering Cells" in the Diagnosis of Aspiration Pneumonia | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

The Clinical Application Value of "Showering Cells" in the Diagnosis of Aspiration Pneumonia

A Case-Control Study on the Clinical Application Value of "Showering Cells" in the Diagnosis of Aspiration Pneumonia

NCT07395310•Chinese PLA General Hospital

View on ClinicalTrials.gov

Summary

Based on our team's previous discovery of a unique type of squamous epithelial cell in the bronchoalveolar lavage fluid (BALF) of patients with aspiration pneumonia (AP) using microbiological rapid on-site evaluation (M-ROSE) technology-characterized by its distinct morphology and absence of bacterial adhesion on the surface-which we termed "showering cells," we designed a diagnostic test case-control study. Adult patients with pulmonary infection scheduled to undergo bronchoscopy were screened and allocated into an AP group (experimental group) and a non-AP group (control group). BALF sampling and M-ROSE slide preparation were performed following a standardized protocol. Microscopic examination was conducted to detect and manually count "showering cells." Simultaneously, a committee of respiratory and critical care medicine experts determined the gold-standard diagnosis (AP or non-AP) based on composite clinical criteria. A 2×2 contingency table was constructed to calculate sensitivity, specificity, positive/negative likelihood ratios, positive/negative predictive values along with their 95% confidence intervals, and the kappa agreement rate. A receiver operating characteristic (ROC) curve was plotted to evaluate the diagnostic performance of "showering cells" for aspiration pneumonia, from which the area under the curve (AUC) was calculated and the optimal cutoff value determined. This study aims to assess the diagnostic utility of "showering cells" and provide a novel cytomorphological tool for the diagnosis of aspiration pneumonia.

Eligibility

Age

18 - 100 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Aged 18 to 100 years, inclusive. No absolute contraindications to bronchoscopy and consent to undergo flexible bronchoscopy.
•Hospitalized patients who either meet the diagnostic criteria for aspiration pneumonia or have aspiration pneumonia definitively ruled out.
•AP Group：
•1. Imaging Findings:Newly developed dependent infiltrates on chest CT (gravity-dependent distribution of new lung infiltrates). Specifically, in the standing/sitting position, infiltrates are predominantly seen in the basal segments of the lower lobes, especially the right lower lobe. In the supine position, infiltrates are primarily located in the posterior segment of the right upper lobe and the dorsal segment of the right lower lobe. These may be accompanied by a small amount of pleural effusion or plate-like atelectasis.
•2. Clinical History Characteristics:A clear history of aspiration or the presence of at least one high-risk factor for aspiration (e.g., impaired consciousness: sedated state, post-stroke, epileptic seizure; confirmed swallowing dysfunction; gastroesophageal reflux disease; abnormal gag reflex/diminished cough reflex; poor oral hygiene: periodontitis, inadequate denture cleaning; end-stage disease: advanced dementia, malignancy, etc.).
•2.Meeting 2 or more of the following 3 clinical criteria:（1）.Temperature abnormality: Fever (core temperature \>38.0°C) or hypothermia (core temperature \<36.0°C, more common in elderly or immunocompromised patients).(2).Respiratory symptoms: New onset or worsening of cough, production of purulent sputum (may contain food particles or unusual odor), dyspnea, chest pain, or detection of food particles/gastric contents in tracheal secretions.(3).Abnormal peripheral inflammatory markers: White blood cell count \>10×10⁹/L or \<4×10⁹/L, or presence of a left shift (band neutrophil proportion \>5%).
•Non-AP Group:
•1. Imaging: Chest CT reveals newly appeared or progressive pulmonary infiltrates, consolidation, or ground-glass opacities.
•2. Clinical Criteria: Meeting 2 or more of the following 3 criteria:
•（1).Fever (core temperature \>38.0°C) or hypothermia (core temperature \<36.0°C, more common in elderly or immunocompromised patients).
+3 more criteria

Exclusion Criteria

•1. Younger than 18 years old or older than 100 years old.
•2. Patients with absolute contraindications to performing bronchoscopy with bronchoalveolar lavage (BAL);
•3. Patients who refuse to participate in the study.

Locations (1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

January 1, 2026

Primary Completion Date

October 31, 2029

Completion Date

December 31, 2029

Last Updated

February 9, 2026

Enrollment

ESTIMATED participants

Conditions

Pneumonia, Aspiration

Inhaled Nitric Oxide Study for Respiratory Failure in Newborns

NCT00005776

Infant, NewbornHypertension, Pulmonary+4 more

View study

COMPLETEDPHASE3

BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia

NCT01045902

Pneumonia, AspirationLung Abscess

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 9, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions